Drug Profile


Alternative Names: Aponeurin

Latest Information Update: 25 Jan 2011

Price : $50

At a glance

  • Originator Neuraxo Biopharmaceuticals
  • Class
  • Mechanism of Action Collagen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Stroke

Most Recent Events

  • 25 Jan 2011 No development reported - Preclinical for Stroke in Germany (unspecified route)
  • 29 Jul 2005 Aponeurin is available for licensing or partnering(http://www.neuraxo.com)
  • 18 Apr 2005 Preclinical trials in Stroke in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top